Author

Daniel J. O'Connor

Association of the British Pharmaceutical Industry

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:benchmark study· 1 Research Focus:benchmarking· 1 Research Focus:database / resource· 1 Research Focus:software / tool· 1 Approach:statistical model· 1

Frequent Co-Authors

Alice E. DavidsoniD· 1 shared Ana Lisa Tavares· 1 shared Andrew G. L. DouglasiD· 1 shared Carlo RinaldiiD· 1 shared Carme CampsiD· 1 shared Catherine Ryan· 1 shared David S. LynchiD· 1 shared Ella F. WhittleiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Alice E. DavidsonORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A scalable and equitable framework for target and patient prioritisation in rare disease antisense therapeutics

Ella F. Whittle, Kylie Montgomery, Carme Camps, Nour M. Elkhateeb, Catherine Ryan, Sara Aguti, Thales A. C. de Guimarães, Usha Kini, Helen S. Stewart, Andrew G. L. Douglas, Louise C. Wilson, Harry G. Leitch, David S. Lynch, Robert A. Robinson, Michel Michaelides, , Mina Ryten

The paper presents a framework for prioritizing targets and patients for antisense oligonucleotide therapies in rare diseases, focusing on equitable and systematic decision-making.

medRxiv · Mar 26, 2026 · PreprintGenetic & Genomic Medicine